Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.

Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2023

Cited by 0